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Background: Physical activity has been shown to decrease cardiovascular mortality and morbidity. Walking, a simple physical
activity which is an integral part of daily life, is a feasible and safe activity for patients with heart failure (HF). A step counter,
measuring daily walking activity, might be a motivational factor for increased activity.
Objective: The aim of this study was to examine the association between walking activity and demographical and clinical data
of patients with HF, and whether these associations could be used as predictors of walking activity.
Methods: A total of 65 patients with HF from the Future Patient Telerehabilitation (FPT) program were included in this study.
The patients monitored their daily activity using a Fitbit step counter for 1 year. This monitoring allowed for continuous and safe
data transmission of self-monitored activity data.
Results: A higher walking activity was associated with younger age, lower New York Heart Association (NYHA) classification,
and higher ejection fraction (EF). There was a statistically significant correlation between the number of daily steps and NYHA
classification at baseline (P=.01), between the increase in daily steps and EF at baseline (P<.001), and between the increase in
daily steps and improvement in EF (P=.005). The patients’ demographic, clinical, and activity data could predict 81% of the
variation in daily steps.
Conclusions: This study demonstrated an association between demographic, clinical, and activity data for patients with HF that
could predict daily steps. A step counter can thus be a useful tool to help patients monitor their own physical activity.
Trial Registration: ClinicalTrials.gov NCT03388918; https://clinicaltrials.gov/ct2/show/NCT03388918
International Registered Report Identifier (IRRID): RR2-10.2196/14517
(JMIR Biomed Eng 2020;5(1):e20776) doi: 10.2196/20776
JMIR Biomed Eng 2020 | vol. 5 | iss. 1 | e20776 | p. 1http://biomedeng.jmir.org/2020/1/e20776/
(page number not for citation purposes)




heart failure; cardiovascular rehabilitation; step counters; physical activity; telerehabilitation
Introduction
Cardiovascular diseases account for 13%-15% of all deaths
worldwide and 24.8% in Europe and are thereby the leading
cause of mortality [1-4]. Heart failure (HF) is one of the most
common cardiovascular causes of mortality [4,5], with a
prevalence of 0.4%-2% among the general population and
2.3%-16% among people aged over 75 [6]. Physical activity
has been proven to decrease cardiovascular mortality and
morbidity [3,7,8] and has therefore been a main focus of
rehabilitation programs targeting lifestyle changes [3,7] in order
to improve patient recovery. Generally, cardiac rehabilitation
includes interventions such as physical activity, improved diet,
and weight control, with the aim of improving patients’
recovery, functional capacity, psychosocial well-being, and
quality of life [3,9,10]. However, participation in rehabilitation
programs is often low. In order to increase adherence,
rehabilitation programs have been introduced that are more
accessible and individualized for the patient, such as home-based
cardiac rehabilitation programs involving cardiac
telerehabilitation [3,11,12]. Telerehabilitation is defined as
rehabilitation activities using information and communication
technologies [13].
Walking, a simple physical activity, is an integral part of our
daily routine [14] and is suitable for cardiac patients. Walking
is both safe and feasible for almost all patients with HF [3].
Today, many self-tracking devices provide information to users
regarding their walking activity, such as the number of steps,
and may therefore assist patients to monitor their walking. Such
self-tracking devices are based on sensor technologies that allow
continuous monitoring of physiological data by the walker in
the context of everyday life [12]. Telemonitoring concepts
including smart device–based monitoring, especially
measurements of physical activity, are considered to be
beneficial for patients with HF [3,12,15].
People are considered physically active if they perform more
than 30 minutes of moderate to intense physical activity per
day; this would be equivalent to approximately 7000-10,000
steps per day [3,8]. However, studies of walking activity among
cardiac patients have found that these patients walked a mean
number of 5889 [3], 7027 [15], and 5869 [12] daily steps. These
3 studies included patients suffering from acute coronary
syndrome, coronary artery disease [15], and HF [12], as well
as those who underwent coronary artery bypass repair or valve
replacement [3].
Bäck et al [15] presented a step index that describes the walking
activity for cardiac patients, in which less than 3000 steps per
day represent low activity, 3000-9999 steps per day represent
medium activity, and over 10,000 steps per day represent high
activity. Bäck et al [15] found that 11.18% of the study
population had a low activity level, 69.65% a medium activity
level, and 19.17% a high activity level. This same tripartite
classification was also used by Thorup et al [3] to categorize
the walking activity of cardiac patients, where 22% of the study
population were classified as having a low activity level, 64%
medium, and 14% high.
Based on the initial findings from the research literature and
from pilot studies, the Future Patient Telerehabilitation (FPT)
program proposed a new approach to telerehabilitation for
patients with HF to increase their quality of life and educate
them to monitor any worsening of their symptoms. The patients
used self-tracking devices for monitoring physical activity,
blood pressure, sleep, respiration, and pulse [11]. In the FPT
program, recorded data from the daily measurements were
available on a shared web platform called the HeartPortal used
by patients, their relatives, and health care professionals [11].
In this paper, we report on a substudy of FPT focusing on the
walking activity of patients with HF in a telerehabilitation
program over 1 year. Our aim is to explore (1) the duration of
usage of the step counter devices; (2) the eventual increase in
the average number of daily steps; (3) the correlation between
the number of daily steps with ejection fraction (EF), New York
Heart Association (NYHA) class [16], and age, respectively;
and (4) whether baseline EF, NYHA class, age, or gender can
be used to predict the daily number of steps.
Methods
Future Patient Telerehabilitation Program
This substudy utilizes the data from the intervention group that
received telerehabilitation (TR group) of the FPT
(ClinicalTrials.gov: NCT03388918 and the Danish Ethical
Committee: N-20160055). The TR group participated in the
telerehabilitation program, whereas the control group followed
a conventional rehabilitation program at the health care center.
The intervention in the FPT consisted of 3 phases: (1) Education
and titration of medicine (0-3 months), (2) Telerehabilitation
in health care center or call center (approximately 3 months),
(3) Daily monitoring via telerehabilitation (approximately 6
months), corresponding to a follow-up of 12 months [11].
During the participation period, the patients in the TR group
received a blood pressure device, weight scale, sleep sensor,
step counter, and an iPad. In addition, they were also given
access to the HeartPortal, which is a digital toolbox developed
on the basis of patient feedback [17], that functions as an
interactive learning module. The HeartPortal consists of (1) an
interactive information site for patient education, (2) a
communication platform enabling patients to communicate
directly with health care professionals via online messages, (3)
visualization of measured values, and (4) patient-reported
outcomes data [11].
Based on the study by Munck et al [18], evaluating self-tracking
devices for telerehabilitation of patients with HF, Fitbit step
counters were used in the FPT, as these received the highest
user evaluation and the lowest step count error percentages. The
choice of the Fitbit device is consistent with the systematic
review by Bunn et al [19], which concludes that Fitbit products
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are generally more accurate regarding step counting compared
with other wearable physical activity trackers [19].
Participants and Recruitment
The target group of the FPT included patients diagnosed with
HF according to the NYHA class I-IV. The patients were
recruited from cardiology wards at hospitals in 4 Danish cities,
all of which were part of the Regional Hospital Central Jutland
[11]. Patients were eligible for the study if (1) they were
diagnosed with HF according to NYHA class I-IV, hereof a
maximum of 20% of the patients were allowed from NYHA
class I, and had experienced an HF-related hospitalization or
visit to the outpatient clinic within the past 2 weeks; (2) the
patient was 18 years of age or older; (3) the patient had to live
in Viborg, Skive, Silkeborg, or Randers municipality; (4) the
patient was living at home and capable of caring for
himself/herself; (5) they had basic computer skills or a relative
who had basic computer skills; and (6) the patient was able to
sign an informed consent form. Furthermore, patients were
excluded if they (1) were pregnant; (2) had a drug addiction
defined as the use of cannabis, opioids, or other drugs; (3) had
previous neurologic, musculoskeletal, or cognitive disability or
active psychiatric history (as noted in the medical record) other
than depression or anxiety related to cardiac or other chronic
illness; (4) lacked the ability to cooperate; or (5) did not speak
Danish.
In total, 140 patients were included in the FPT, of which 70
patients were randomly allocated to the TR group and 70 to the
control group [11]. Of the 70 patients from the TR group, 65
completed the FPT program. Figure 1 (CONSORT
[Consolidated Standards of Reporting Trials] diagram) illustrates
the randomization procedure, follow-up, and drop out reasons
for the TR group. Multimedia Appendix 1 provides
CONSORT-EHEALTH (Randomized Controlled Trials of
Electronic and Mobile Health Applications and Online
TeleHealth) checklist.
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Figure 1. CONSORT diagram of the Future Patient trial. CONSORT: Consolidated Standards of Reporting Trials.
Walking Activity
One of the clinical measures used in the FPT was the patients’
activity level, which was recorded using a Fitbit step counter,
either Fitbit Zip or Fitbit Charge HR [11]. These step counters
were selected based on the results presented in Munck et al [18],
which found these Fitbit step counters to have the lowest error
margin. Both devices calculate steps based on data from the
internal 3-axis accelerometer, and the step data were acquired
every 20 minutes using application programming interface
(API). All patients were asked to wear the step counter during
all waking hours, from 8 am to 9 pm, during the course of the
project period.
To account for single days of missing values from the step
counters, the median value of daily steps during a week has
been evaluated and used as the indicator of the general activity
level for the patient for that particular week.
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The duration of time in which the patients have used the step
counters was defined as the number of active days compared
to (1) the total number of days enrolled in the study, (2) EF,
and (3) NYHA classification. So-called active days have been
defined as days with more than 100 steps per day. This 100-step
cut-off point was the same as that presented in Thorup et al [3],
in order to avoid faulty measurements when the step counter
was moved around but not worn. In addition, activity levels
were classified as low, medium, or high, following Bäck et al
[15].
Data Acquisition
Clinical data (weight, blood pressure, heart rate, EF determined
through a standardized transthoracic echocardiography, NYHA
classification, and etiology of HF) and sociodemographic data
(age, gender, civil status, education level, and work status) were
acquired from the patient’s medical journal or through
self-reporting. Data on the patient’s daily activity were acquired
from Fitbit every 20 minutes using API and consisted of the
number of steps taken.
Statistical Analysis
Prior to analysis, data were examined regarding the normality
of the distribution using a Shapiro–Wilk test.
To investigate how long the patients chose to use the step
counter and the progression of steps, a one-way analysis of
variance (ANOVA) with repeated measures was used.
The association between the activity and clinical parameters
was investigated using Pearson correlation coefficient, which
determines the covariance of 2 variables divided by the product
of their standard deviations.
A linear hierarchical regression analysis was used to determine
whether demographic, clinical, and activity parameters can be
used to explain a statistically significant amount of variance in
the mean number of steps. These were presented in different
blocks, of which the first block contained demographic data
(age and gender), the second block contained clinical data
(baseline EF and baseline NYHA), and the third block contained
activity data (baseline number of daily steps).
The statistical analysis was performed using SPSS Statistics
version 25 (IBM, Inc.).
Results
Patient Characteristics
The patient characteristics of the TR group are presented in
Table 1.
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Table 1. Patient characteristics at baseline.
ValuesVariable
Follow-upa (N=65)Baseline (N=65)















84.53 (22.37)85.19 (20.55)Mean (SD)
51.60-16856-166Range
69.53-96.65 (n=54)70.03-98.525th-75th percentile
Systolic blood pressure (mmHg) (n=65)
116.98 (16.45)124.17 (17.62)Mean (SD)
83-15284-172Range
105-128.25 (n=40)112.75-134.2525th-75th percentile
Diastolic blood pressure (mmHg) (n=65)
72.45 (10.08)79.08 (11.14)Mean (SD)
46-9348-122Range
66.50-78.75 (n=40)70.75-8625th-75th percentile
Heart rate (beats/minute) (n=65)
68.11 (16.36)78.35 (17.72)Mean (SD)
41-11646-119Range
57-77 (n=40)66-90.525th-75th percentile
Ejection fraction (%) (n=65)








Etiology of heart failure, n (%)
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—43 (66)From visit in outpatient clinic
Civil status, n (%)
—23 (35)Single









Work status, n (%)
—0 (0)Unemployed
—19 (29)Sick leave
—5 (8)Works under 20 hours/week
—2 (3)Works 20-36 hours/week
—9 (14)Works full-time 37 hours/week
—30 (46)Retired
aThere are missing data from some patients for the clinical parameters at follow-up. The number of patients, for whom the data were available within
2 months prior to follow-up, is stated in parentheses.
bNYHA: New York Heart Association.
Usage of Step Counter
Table 2 focuses on activity and its relation to clinical and
demographical data. The overall period during which the patients
used the step counter in relation to their activity level is shown
in Table 2. This duration is presented as the total number of
days in which the patients were enrolled in the study and the
number of active days in which they were using the step counter.
Also presented in the table are their EF and NYHA
classifications and gender with regard to the different activity
levels.
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Table 2. Duration of step counter use with regard to the patients’ activity levels.





Days using step counter, mean (SD)
.208338.1 (26.61)358.04 (56.77)384.13 (61.53)358.18 (54.57)Total days
.966317.10 (55.42)319.32 (92.32)310.63 (90.11)317.91 (86.34)Active days
.36594.40 (16.94)88.74 (20.12)81.00 (20.56)88.65 (19.75)Activity days/total days (%)
Clinical variables
.78830.75 (8.98)32.19 (8.60)30.31 (8.50)31.74 (8.54)Ejection fraction (%), mean
(SD)
.057NYHAa classification, n (%)
2 (20)8 (80)0 (0)10 (100)I
6 (15)31 (76)4 (10)41 (100)II
2 (17)7 (58)3 (25)12 (100)III
0 (0)1 (50)1 (50)2 (100)IV
Sociodemographic characteristics
.659Gender, n (%)
8 (16)36 (73)5 (10)49 (100)Male
2 (13)11 (69)3 (19)16 (100)Female
aNYHA: New York Heart Association.
Table 2 shows that overall, patients used the step counter
88.65% of the total period in which they were enrolled in the
study, and that the time interval in which they use the step
counter increased in line with increases in the activity level.
Increase in the Number of Daily Steps
During all 3 rehabilitation phases, the patients walked a mean
number of 6962.81 (SD 3630.74) daily steps, with a minimum
of 227 daily steps and a maximum of 25,499 daily steps. The
mean number of daily steps during the 3 different phases were
5868.56 (SD 3912.34) daily steps in phase I, 7233.89 (SD
4197.36) daily steps in phase II, and 7338.58 (SD 4359.67)
daily steps in phase III. These mean values are calculated from
the different phases which had a duration of 0-3 months in phase
I, 3 months in phase II, and 6 months in phase III.
A one-way ANOVA with repeated measures showed that the
mean number of steps was not significantly different across the
3 phases (F2,62=1.137, P=.318). Furthermore, a one-way
ANOVA with repeated measures using gender (F2,62=0.015,
P=.978), EF (F2,62=2.585, P=.87), and NYHA classification
(F2,62=2.229, P=.119) as covariates showed that the mean
number of steps was not significantly different across the 3
phases.
Figure 2 presents the mean number of daily steps in bar plots
with regard to the gender of the patients, the 3 phases of the
FPT, EF with a threshold of 30%, and the patient’s NYHA
classification.
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Figure 2. Bar plots of the mean number of steps with regard to (A) gender, (B) phase of the study, (C) EF, and (D) NYHA classification. The SDs are
illustrated as error bars. Note: Only 63 of the 65 patients used their step counter in phase III. Hence, the mean numbers of steps illustrated in B is only
a mean from these 63 patients. EF: ejection fraction; NYHA: New York Heart Association.
Although none of the differences in means are statistically
significant, tendencies appear in the plots with regard to gender,
EF, and NYHA. Between males and females, it appears that
males have a higher mean number of daily steps than females,
patients with an EF lower than 30% walk less than patients with
an EF over 30%, and patients with a lower NYHA classification
walk more than patients with a higher NYHA classification.
Correlation Between Daily Steps and Clinical
Parameters
The correlation between daily steps and demographic and
clinical parameters was investigated using Pearson correlation
coefficient. The investigated parameters were age, gender,
baseline EF, change in EF, baseline NYHA, change in NYHA,
mean number of steps, and change in number of daily steps.
The correlation values (r) and corresponding P values are
presented in Table 3.
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0.0531.000Mean number of daily steps
1.000Change in daily steps
aEF: ejection fraction.





Based on the correlation coefficients and significance levels in
Table 3, a statistically significant correlation of P<.05 appears
between the following variables: (1) the baseline EF and change
in EF, (2) the baseline EF and baseline NYHA, (3) the baseline
EF and change in the number of daily steps, (4) change in EF
and change in the number of daily steps, (5) the baseline NYHA
and change in NYHA classification, and (6) the baseline NYHA
classification and mean number of daily steps.
Regression Analysis
Hierarchical regression analyses have been performed with the
following purposes: (1) predicting the variation in the mean
number of steps and (2) predicting the variation in the change
in EF. Both analyses consisted of 3 models in which
demographic data were entered in the first block, clinical data
in the second block, and activity data in the third block. The
results from the analyses are presented in Table 4.
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Table 4. Hierarchical regression analyses to predict the mean number of steps, depicted as model statistics and coefficients.
Prediction of variation in the mean number of stepsModel and variables
CoefficientsTest statistics
















bNYHA: New York Heart Association.
cP<.05.
The squared correlations (R2) shown in Table 4 indicate the
proportion of variation accounted for when using the variables
listed under the model numbers, which in these cases increases
with the complexity of the model. The result in model 3 prove
that 81% of the variation in the mean steps can be predicted.
The correlation for model 3 is highly influenced by the baseline
EF and baseline steps variables, as these were the statistically
significant predictors (P=.006 and P<.001, respectively), based
on the P values.
Discussion
Principal Findings
The aim of this FPT substudy was to investigate the walking
activity of patients with HF participating in a telerehabilitation
program for 1 year as measured by step counters. There was no
statistically significant difference (P>.05) between the mean
number of daily steps in the 3 phases of the intervention. This
may be due to the step counters not being designed to capture
different modes of physical activity (eg, cycling and swimming).
As a result, not all physical activities may have been
documented.
This study has shown a significant correlation between the mean
number of daily steps and NYHA classification (P=.01),
between the increase in daily steps and EF (P<.001), and
between the increase in daily steps and reduction in EF (P=.005).
These correlations indicate a relationship between a higher level
of physical activity and an improvement in the HF condition.
Furthermore, the findings indicate that demographic, clinical,
and activity data can be used to predict 81% of the variation in
the mean number of daily steps.
A study by Albert et al [20] investigating the requirements from
patients with HF regarding devices for monitoring their health
and activity found that the patients with HF requested devices
that could give them immediate feedback and an overview of
data over time [20]. In our study, we used 2 Fitbit step counters,
both of which fulfilled these requests. Hence, they gave the
patients immediate feedback through the device and an overview
of their own data using the HeartPortal [17]. These commercially
available devices could therefore be used to encourage the
patients to be more active in their daily lives. During this period,
the patients participated in a mean total duration of 358.18 (SD
54.57) days, and they used the step counters for mean 88.65%
(SD 19.75%) of this time (they were asked to use the Fitbits
every day). However, the percentage of time using the step
counter differed between the predefined activity levels because
patients with a low activity level used the step counter for
81.00% (SD 20.56%) of the participation period, whereas those
patients with a high activity level used the step counter for
94.40% (SD 16.94%) of the participation period. These results
seem to indicate that a higher adherence is associated with a
higher activity level. These findings are consistent with those
reported by Thorup et al [3], wherein 72% of the low-activity
level cardiac patients walked a minimum of 100 steps with a
Fitbit step counter, compared to 88% of those with a medium
activity level and 91% of those with a high activity level.
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The patients in the FPT walked a mean number of 6962.81 steps
daily, which is approximately the same as the mean number of
7027 daily steps reported by Bäck et al [15], whose study also
included patients with coronary artery disease. However, the
mean number of steps in this study is higher than the mean
number of 5889 and 5869 steps reported by Thorup et al [3]
and Werhahn et al [12], who either included different cardiac
patients (including patients with HF) or only patients with HF.
The hierarchical regression analyses demonstrated that it is
possible to predict 81% of the variation in the mean daily steps.
However, only the baseline EF (P=.006) and the baseline
number of daily steps (P<.001) were statistically significant
predictors when predicting variation in the mean number of
daily steps.
The relations between clinical variables and daily steps
presented in this study can be of value in clinical practice first
for the patients. Besides, in collaboration with health care
professionals, these data can help facilitate the rehabilitation of
patients with HF. This is in alignment with a previous study
conducted by the Laboratory for Welfare Technology, which
reported that the use of step counters motivated cardiac patients
to do more physical activity and made the physical activity
visible for the patient [21]. A qualitative study by Andersen et
al [22] showed that activity data from wearable devices used
by cardiac patients may be a tool for self-care.
To our knowledge, no other studies have included patients with
HF and measured and analyzed step counts over a 1-year period.
We believe that this study offers a picture of how an activity
tracker can be used to document the change in the physical
activity over time for patients with HF in their daily lives.
Limitations
Some limitations of this study should be considered. The
echocardiograph was not blinded for other clinical information,
which may have led to biases. Two different kinds of step
counters were used due to patient preferences. However, the 2
types of step counters used in the FPT were among those models
with the lowest error margin, as described in Munck et al [18],
and are therefore considered valid.
Conclusions
The patients in this study who walked more tended to be of a
younger age, had lower NYHA classification, and a higher EF.
There was a statistically significant correlation between the
mean number of daily steps and the NYHA classification at
baseline (P=.01), between the increase in daily steps and EF at
baseline (P<.001), and between the increase in daily steps and
improvement in EF (P=.005). The patients’ demographic,
clinical, and activity data can be used to predict 81% of the
variation in the mean number of daily steps. These results
suggest that a step counter may be a useful tool for patients in
helping them to monitor their own physical activity during a
telerehabilitation program and a means to help enhance their
recovery.
Acknowledgments
The authors would like to acknowledge the Aage and Johanne Louis-Hansen’s Foundation for making this study possible.
Furthermore, the authors would like to thank all partners in the project: Healthcare centers in Viborg, Skive, Randers, and
Silkeborg; the cardiology wards at the regional hospitals in Viborg, Skive, Randers, and Silkeborg; the Danish Heart Association;
Technical University of Denmark; Department of Psychology and Behavioral Sciences at Aarhus University; Department of
Computer Science at Aalborg University; CIMT at Odense University Hospital; and Laboratory for Welfare Technologies at
Aalborg University. The Future Patient project is financed by Aage and Johanne Louis-Hansen’s Foundation, Aalborg University,
Viewcare, and partners in the project.
Authors' Contributions
The study was designed by BD, HS, MH, and JR. JG and BD have drafted the manuscript. Feedback for the manuscript was




CONSORT-EHEALTH checklist (V 1.6.1).
[PDF File (Adobe PDF File), 1088 KB-Multimedia Appendix 1]
References
1. Savarese G, Lund L. Global Public Health Burden of Heart Failure. Card Fail Rev 2017 Apr;3(1):7-11 [FREE Full text]
[doi: 10.15420/cfr.2016:25:2] [Medline: 28785469]
2. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol 2014
Feb 15;171(3):368-376. [doi: 10.1016/j.ijcard.2013.12.028] [Medline: 24398230]
JMIR Biomed Eng 2020 | vol. 5 | iss. 1 | e20776 | p. 12http://biomedeng.jmir.org/2020/1/e20776/
(page number not for citation purposes)
Gade et alJMIR BIOMEDICAL ENGINEERING
XSL•FO
RenderX
3. Thorup C, Hansen J, Grønkjær M, Andreasen JJ, Nielsen G, Sørensen EE, et al. Cardiac Patients' Walking Activity
Determined by a Step Counter in Cardiac Telerehabilitation: Data From the Intervention Arm of a Randomized Controlled
Trial. J Med Internet Res 2016 Apr 04;18(4):e69 [FREE Full text] [doi: 10.2196/jmir.5191] [Medline: 27044310]
4. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, American Heart Association Advocacy
Coordinating Committee, Stroke Council, Council on Cardiovascular RadiologyIntervention, Council on Clinical Cardiology,
Council on EpidemiologyPrevention, Council on Arteriosclerosis, ThrombosisVascular Biology, Council on Cardiopulmonary,
Critical Care, PerioperativeResuscitation, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular
Disease, Council on Cardiovascular SurgeryAnesthesia‚Interdisciplinary Council on Quality of CareOutcomes Research.
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
Circulation 2011 Mar 01;123(8):933-944. [doi: 10.1161/CIR.0b013e31820a55f5] [Medline: 21262990]
5. Gensini G, Alderighi C, Rasoini R, Mazzanti M, Casolo G. Value of Telemonitoring and Telemedicine in Heart Failure
Management. Card Fail Rev 2017 Nov;3(2):116-121 [FREE Full text] [doi: 10.15420/cfr.2017:6:2] [Medline: 29387464]
6. Ponikowski P, A. Voors A, D. Anker S, Bueno H, G. F. Cleland J, J. S . Coats A, et al. 2016 ESC guidelines for the diagnosis
and treatment of acute and chronic heart failure. Russ J Cardiol 2017 Jan 01;37(1):7-81. [doi:
10.15829/1560-4071-2017-1-7-81]
7. Houle J, Doyon O, Vadeboncoeur N, Turbide G, Diaz A, Poirier P. Innovative program to increase physical activity following
an acute coronary syndrome: randomized controlled trial. Patient Educ Couns 2011 Dec;85(3):e237-e244. [doi:
10.1016/j.pec.2011.03.018] [Medline: 21546203]
8. Houle J, Valera B, Gaudet-Savard T, Auclair A, Poirier P. Daily steps threshold to improve cardiovascular disease risk
factors during the year after an acute coronary syndrome. J Cardiopulm Rehabil Prev 2013;33(6):406-410. [doi:
10.1097/HCR.0000000000000021] [Medline: 24104407]
9. Louis AA, Turner T, Gretton M, Baksh A, Cleland JG. A systematic review of telemonitoring for the management of heart
failure. Eur J Heart Fail 2003 Oct;5(5):583-590. [doi: 10.1016/s1388-9842(03)00160-0] [Medline: 14607195]
10. Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, Better Effectiveness After Transition–Heart
Failure (BEAT-HF) Research Group. Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients
With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial.
JAMA Intern Med 2016 Mar 01;176(3):310-318 [FREE Full text] [doi: 10.1001/jamainternmed.2015.7712] [Medline:
26857383]
11. Dinesen B, Dittmann L, Gade JD, Jørgensen CK, Hollingdal M, Leth S, et al. "Future Patient" Telerehabilitation for Patients
With Heart Failure: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019 Sep 19;8(9):e14517 [FREE Full
text] [doi: 10.2196/14517] [Medline: 31538944]
12. Werhahn SM, Dathe H, Rottmann T, Franke T, Vahdat D, Hasenfuß G, et al. Designing meaningful outcome parameters
using mobile technology: a new mobile application for telemonitoring of patients with heart failure. ESC Heart Fail 2019
Jun 13;6(3):516-525 [FREE Full text] [doi: 10.1002/ehf2.12425] [Medline: 30868756]
13. Brennan D, Tindall L, Theodoros D, Brown J, Campbell M, Christiana D, et al. A blueprint for telerehabilitation guidelines.
Int J Telerehabil 2010 Oct 27;2(2):31-34 [FREE Full text] [doi: 10.5195/ijt.2010.6063] [Medline: 25945175]
14. Savage PD, Ades PA. Pedometer step counts predict cardiac risk factors at entry to cardiac rehabilitation. J Cardiopulm
Rehabil Prev 2008;28(6):370-7; quiz 378. [doi: 10.1097/HCR.0b013e31818c3b6d] [Medline: 19008690]
15. Bäck M, Cider Å, Gillström J, Herlitz J. Physical activity in relation to cardiac risk markers in secondary prevention of
coronary artery disease. Int J Cardiol 2013 Sep 20;168(1):478-483. [doi: 10.1016/j.ijcard.2012.09.117] [Medline: 23041099]
16. American Heart Association. Classes of Heart Failure Internet. Chicago, IL: American Heart Association; 2020. URL:
https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure [accessed 2020-11-15]
17. Joensson K, Melholt C, Hansen J, Leth S, Spindler H, Olsen MV, et al. Listening to the patients: using participatory design
in the development of a cardiac telerehabilitation web portal. Mhealth 2019;5:33. [doi: 10.21037/mhealth.2019.08.06]
[Medline: 31620460]
18. Munck K, Christensen M, Tahhan A, Dinesen B, Spindler H, Hansen J. Evaluation of Self-Trackers for Use in
Telerehabilitation. J Usability Stud 2018;13(4):37. [doi: 10.5555/3294033.3294035]
19. Bunn J, Navalta J, Fountaine C, Reece J. Current State of Commercial Wearable Technology in Physical Activity Monitoring
2015-2017. Int J Exerc Sci 2018;11(7):503-515 [FREE Full text] [Medline: 29541338]
20. Albert NM, Dinesen B, Spindler H, Southard J, Bena JF, Catz S, et al. Factors associated with telemonitoring use among
patients with chronic heart failure. J Telemed Telecare 2016 Jul 08;23(2):283-291. [doi: 10.1177/1357633x16630444]
21. Thorup CB, Grønkjær M, Spindler H, Andreasen JJ, Hansen J, Dinesen BI, et al. Pedometer use and self-determined
motivation for walking in a cardiac telerehabilitation program: a qualitative study. BMC Sports Sci Med Rehabil 2016 Aug
18;8(1):24 [FREE Full text] [doi: 10.1186/s13102-016-0048-7] [Medline: 27547404]
22. Andersen TO, Langstrup H, Lomborg S. Experiences With Wearable Activity Data During Self-Care by Chronic Heart
Patients: Qualitative Study. J Med Internet Res 2020 Jul 20;22(7):e15873 [FREE Full text] [doi: 10.2196/15873] [Medline:
32706663]
JMIR Biomed Eng 2020 | vol. 5 | iss. 1 | e20776 | p. 13http://biomedeng.jmir.org/2020/1/e20776/
(page number not for citation purposes)




ANOVA: analysis of variance
API: application programming interface
CONSORT: Consolidated Standards of Reporting Trials
CONSORT-EHEALTH: Randomized Controlled Trials of Electronic and Mobile Health Applications and
Online TeleHealth
EF: ejection fraction
FPT: Future Patient Telerehabilitation
HF: heart failure
NYHA: New York Heart Association
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